


Comparing Vitamin D Supplementation Versus Placebo for Urgency Urinary Incontinence: A Pilot Study

Alayne D. Markland, DO, MSc, *[†]  Vin Tangpricha, MD, PhD,[‡] T. Mark Beasley, PhD, *[§] Camille P. Vaughan, MD, MS, *[‡] Holly E. Richter, PhD, MD,[¶] Kathryn L. Burgio, PhD, *[†] and Patricia S. Goode, MD *[†]

OBJECTIVES: To estimate the efficacy of vitamin D supplementation to reduce urgency urinary incontinence (UUI) episodes.

DESIGN: Pilot, two-arm, randomized trial conducted from 2013 to 2017. Interventions were 12 weeks of weekly oral 50,000 IU vitamin D3 or placebo.

SETTING: Academic, university-based outpatient clinic.

PARTICIPANTS: Community-dwelling postmenopausal women, 50 years or older, with at least three UUI episodes on 7-day bladder diary and serum vitamin 25-hydroxyvitamin D (25[OH]D) of 30 ng/mL or less.

MEASUREMENTS: The primary efficacy estimate was the percentage change in UUI episodes. Secondary estimates included changes in other lower urinary tract symptoms, along with exploratory subgroup analysis by race/ethnicity and obesity.

RESULTS: We randomized 56 women (aged 50-84 years; mean = 60.5 ± 8.2 years), 28 to vitamin D and 28 to placebo; 51 completed treatments. Mean serum 25(OH)D at baseline (21.2 ± 5.2 and 18.2 ± 5.6, $P = .30$) improved to 57.9 ± 16.3 ng/mL with vitamin D3 and 21.9 ± 8.2 ng/mL with placebo ($P < .001$). UUI episodes per 24-hour day decreased by 43.0% with vitamin D3 compared to 27.6% with placebo ($P = .22$). Among black women ($n = 33$), UUI episodes decreased by 63.2% with vitamin D3 compared to

22.9% with placebo ($P = .03$). Among obese women, UUI episodes decreased by 54.1% with vitamin D compared to 32.7% with placebo ($P = .29$). For all women, changes in voiding frequency ($P = .40$), nocturia ($P = .40$), urgency ($P = .90$), incontinence severity ($P = .81$), and overactive bladder symptom severity ($P = .47$) were not different between arms.

CONCLUSIONS: Postmenopausal women with UUI and vitamin D insufficiency demonstrated a greater than 40% decrease in UUI episodes, which did not reach statistical significance compared to placebo, except in the subset of black women. The results of this pilot study support further investigation of vitamin D3 alone or in combination with other treatments for UUI, particularly for women in higher-risk subgroups. *J Am Geriatr Soc* 00:1–6, 2018.

Key words: urinary incontinence; vitamin D; postmenopausal women

From the *Department of Veterans Affairs, Birmingham/Atlanta Geriatric Research, Education, and Clinical Center; [†]Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; [‡]Department of Medicine, Emory University, Atlanta, Georgia; [§]Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham; and the [¶]Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.

Address correspondence to Alayne D. Markland, DO, MSc, Division of Gerontology, Geriatrics and Palliative Care, University of Alabama at Birmingham, Department of Medicine, Birmingham Veterans Affairs Medical Center, GRECC/11-G, 700 S 19th St, Birmingham, AL 35233. E-mail: amarkland@uabmc.edu.

Clinicaltrials.gov number: NCT01971801.

DOI: 10.1111/jgs.15711

Treatment of urgency urinary incontinence (UUI) in older women is multicomponent, involving lifestyle, behavioral, and often drug therapy with the potential for adverse events. Identification of novel treatments that maximize the impact of multicomponent therapy and reduce the potential for adverse drug events is needed.

Translational evidence from basic science, epidemiologic research, and small clinical trials provides the rationale for the role of vitamin D to reduce UUI. Vitamin D receptors are present in the bladder detrusor and striated muscle and may be potential treatment targets.^{1,2} Vitamin D may decrease involuntary urgency sensations and improve UUI via better regulation of stromal and smooth muscle growth, thus improving detrusor muscle response to bladder filling. Cross-sectional studies show conflicting results with regard to prevalent UI among older women with low serum vitamin 25-hydroxyvitamin D (25[OH]D).^{3,4} One longitudinal study found women with higher dietary vitamin D intake had

decreased risk of incident overactive bladder (OAB) and UI⁵, whereas other studies found mixed associations between incident UI and low 25(OH)D levels.^{6,7} Separate clinical trials in women reported improvement in UUI with higher vs lower dosages of either vitamin D or a vitamin D analog vs placebo.^{8,9}

To explore whether correction of vitamin D deficiency improves UUI symptoms in postmenopausal women, we conducted a pilot randomized study of vitamin D supplementation in older women with both UUI and vitamin D insufficiency (serum 25[OH]D levels, lower than 30 ng/mL).

METHODS

Study Design

This was a pilot randomized, double-blind, placebo-controlled trial to estimate the effect of vitamin D supplementation for treatment of UUI. The University of Alabama at Birmingham's institutional review board approved the study, and all participants signed informed consent. Enrollment occurred from January 2013 to May 2017.

Participants

Participants were postmenopausal, community-dwelling women, aged 50 years or older, with predominant UUI (3.0 or more episodes per 7 days). Supplemental Table 1 lists inclusion and exclusion criteria. Recruitment occurred through specialty continence care clinics and primary care clinics, public announcements, mailings, and advertisements.

Clinical evaluation consisted of a medical and continence history, physical examination, mental status screening with the Mini-Cog[®],¹⁰ urinalysis, serum 25(OH)D level, and, for participants with diabetes, a glycosylated hemoglobin. Postvoid residual determination by ultrasound was performed. Participants then completed a 7-day bladder diary. Inclusion required participants to have a 25(OH)D level lower than 30 ng/mL. Serum 25(OH)D levels were measured using the IDS iSYS automated system (Gaithersburg, MD) meeting National Institutes of Health (NIH) National Institute of Standards and Technology (NIST)/NIH Vitamin D Metabolites Quality Assurance Program (VitDQAP) standards for accuracy.¹¹

Randomization and Intervention

Using a computer-generated 1:1 allocation ratio, participants were randomized to receive weekly oral 50,000 IU vitamin D3 or placebo for 12 weeks (Tishcon Corp, Salisbury, MD). All patients and study personnel were blinded to treatment assignment. Participants were seen in the clinic for four visits: screening, randomization, 6 weeks, and 12 weeks.

Descriptive Variables

Descriptive data included self-reported race/ethnicity, current insurance status and current use of tobacco, list of medications, prior UI treatment, prior hysterectomy, and parity. From the medication list, diuretics (loop, thiazide, and potassium sparing) were identified. The Functional Comorbidity Index was used to measure the number of chronic comorbid diseases.¹² Adiposity status was computed using body mass

index (BMI; kg/m²) and classified as nonobese (29.9 kg/m² or less) or obese (30 kg/m² or greater). Waist circumference was measured 2.5 cm above the umbilicus.

Outcome Assessments for Efficacy Estimates

The primary outcome was the percentage change in frequency of UUI, as documented in the 7-day bladder diary.¹³ Diaries were abstracted by a blinded study coordinator. For every void and episode of urine loss, participants recorded the presence and severity of urgency using the Indevus Urgency Severity Scale, a rating scale from 1 to 3.¹⁴

Secondary patient-reported measures included changes in symptom questionnaires, condition-specific quality of life, satisfaction with treatment, and safety of the treatments. The International Consultation on Incontinence Modular Questionnaire (ICIQ)-UI was used to measure UI severity (range, 0-21).^{15,16} The ICIQ-OAB questionnaire was used to assess the severity of OAB symptoms (range, 0-16 [four items]).¹⁷ A validated measure was used to assess patient satisfaction and perception of improvement with treatment using a five-point Likert scale (very dissatisfied to very satisfied and much better to much worse).¹⁸

Side effects and unanticipated events were collected by the participant's self-report at telephone visits and at the 6- and 12-week in-person visits. Blood samples were analyzed to monitor changes in calcium, albumin, and vitamin D levels at 6 and 12 weeks. Pill counts were used to assess adherence to drug therapy.

Other secondary outcomes related to possible mechanisms of improvement included pelvic floor muscle strength (Brink's score) before/after treatment,¹⁹ anal sphincter strength (Digital Rectal Examination Scoring System score),²⁰ and the Timed Up and Go Test, a validated measure of mobility.²¹

Power Calculations

The primary aim was to estimate change in UUI episodes over time with vitamin D supplementation compared to placebo to design and power a larger, more definitive efficacy trial. We calculated that 200 participants (100 in each group) were required to achieve 80% power, assuming a two-tailed type I error rate of 0.05, a common SD of change of 3.0 episodes per week, and a clinically relevant 1.2 episodes per week greater decrease in the vitamin D arm compared to placebo. With this pilot study, we examined whether our a priori clinically relevant effect size of a reduction of at least 1.2 episodes/week (40% decrease from the inclusion criterion of three or more episodes/week) was in the 95% confidence interval for the difference between the two treatment means. We conducted a preplanned interim analysis, and the conditional power was less than 60%; thus, the treatment differences were less than 1.2 episodes/week.

Statistical Analyses

We evaluated a completer analysis and an intention-to-treat analysis using last observation carried forward for the primary outcome. The percentage change from baseline to 12 weeks in UUI episodes and secondary outcomes were compared between the two groups using a paired *t* test and the

Table 1. Characteristics of Participants According to Randomization Group¹

Characteristics	Total Group (N = 56)	Vitamin D3 (N = 28)	Placebo (N = 28)	P value
Age (range), y	60.5 ± 8.6 (50-84)	61.4 ± 7.1 (50-84)	59.5 ± 9.2 (50-74)	.37
Race/ethnicity				.08
Non-Hispanic white	16 (29.1)	12 (42.9)	5 (17.9)	
Non-Hispanic black	39 (70.9)	16 (57.1)	23 (82.1)	
Insurance				
Private	28 (50.0)	13 (46.4)	15 (53.6)	.79
Medicare/Medicaid	22 (39.3)	11 (39.3)	11 (39.3)	.99
Self-pay	11 (19.6)	5 (17.9)	6 (21.4)	.74
BMI, kg/m ²	34.4 ± 8.7	34.9 ± 10.4	33.8 ± 6.6	.63
Obese (BMI ≥ 30 kg/m ²)	36 (64.3)	15 (53.6)	21 (80.8)	.03
Waist circumference, in	40.5 ± 5.6	40.5 ± 5.8	40.5 ± 5.5	.99
No. of medications (prescribed)	4.7 ± 3.9	5.2 ± 4.1	4.2 ± 3.6	.34
Use of diuretics	15 (26.8)	5 (17.9)	10 (35.7)	.23
Current tobacco usage	6 (16.1)	1 (3.6)	8 (28.6)	.02
Prior treatment of UI	21 (37.5)	12 (42.9)	9 (32.1)	.58
Type of prior UI treatment				
Medications	19 (33.9)	11 (39.3)	8 (28.6)	
Pelvic floor muscle exercises	12 (21.4)	7 (25.0)	5 (19.9)	
Surgery	0	0	0	
Functional Comorbidity Index (score)	3.3 ± 2.0	3.4 ± 2.2	3.1 ± 1.9	.60
Diabetes	11 (19.6)	3 (10.7)	8 (28.6)	.18
Hypertension	30 (58.6)	11 (39.9)	19 (67.9)	.06
Congestive heart failure	2 (3.6)	0	2 (7.1)	.50
Hysterectomy	32 (57.1)	20 (74.1)	12 (44.4)	.05
Parity	2.8 ± 1.6	2.6 ± 1.4	3.0 ± 1.8	.29
Baseline total UUI episodes/d	3.2 ± 1.6	2.6 ± 2.1	3.7 ± 2.6	.05

Abbreviations: BMI, body mass index; UI, urinary incontinence; UUI, urgency UI.
¹Data are given as mean ± SD or number (percentage).

Wilcoxon signed rank test, when appropriate, along with 95% confidence intervals (CIs). Multivariable models were constructed to estimate 95% CI for treatment effects after controlling for demographics and baseline characteristics. Point estimates and conditional power were performed using SAS version 9.0 statistical software (SAS Institute, Cary, NC).

RESULTS

Supplemental Figure 1 summarizes participant recruitment, enrollment, randomization, and completion. Serum 25(OH)D

level greater than 30 ng/mL was the primary reason for exclusion (70% of the participants enrolled). No differences in dropout rates were noted from the vitamin D arm compared to placebo (11% vs 7%; *P* = 1.0) or among women who did not complete their bladder diary (18% vs 11%; *P* = .7).

Most baseline demographics did not differ across treatment arms (Table 1). Women in the active vitamin D arm, compared to the placebo arm, reported less current tobacco usage, higher rates of prior hysterectomy, and less obesity, despite no difference in mean BMI. UUI episodes were lower at baseline in the vitamin D arm compared to the placebo




Figure 1. Comparison of the percentage change in urgency urinary incontinence episodes for women randomized to vitamin D and placebo for the completer analysis, intention-to-treat analysis, and higher-risk subgroups.

Table 2. Secondary Outcomes From Questionnaire and Examination Data at Baseline and After Treatment With Vitamin D3 and Placebo (N = 56)¹

7-d Bladder Diary Outcomes	Vitamin D3, Mean (SD)			Placebo, Mean (SD)			Overall P Value ³
	Baseline	Posttreatment	P Value ²	Baseline	Posttreatment	P Value ²	
Total UUI episodes/d	2.60 (2.13) (n = 28)	1.57 (2.75) (n = 23)	.04	3.68 (2.58) (n = 28)	2.33 (2.73) (n = 25)	.006	.62
Average voids/d	7.68 (2.58) (n = 28)	7.20 (2.64) (n = 22)	.09	9.03 (8.90) (n = 28)	8.90 (4.19) (n = 25)	.565	.40
Average voids/night	1.50 (1.24) (n = 28)	1.26 (1.22) (n = 22)	.37	2.09 (1.74) (n = 27)	1.51 (1.79) (n = 25)	.036	.40
Average urge rating/d	1.95 (0.85) (n = 28)	1.57 (0.61) (n = 20)	.04	1.85 (0.59) (n = 28)	1.48 (0.62) (n = 25)	.016	.91
Average urge rating/night	1.29 (0.54) (n = 26)	1.26 (0.64) (n = 17)	.79	1.59 (0.72) (n = 26)	0.88 (0.64) (n = 23)	<.001	.010
Symptom Severity Questionnaires	Baseline (N = 28)			Posttreatment (N = 28)			
ICIQ-UI	11.6 (5.4)	6.6 (4.5)	.006	12.5 (4.9)	6.9 (5.4)	.002	.81
ICIQ-OAB	9.6 (2.9)	7.3 (2.8)	.02	10.1 (3.0)	7.1 (3.1)	.002	.47
Improvement and Satisfaction ⁴	6 wk			12 wk			
Improvement (better, much better)	50.0 (10/20)	70.0 (14/20)	.03	40.9 (9/22)	77.2 (17/22)	.09	.22
Satisfaction (completely)	75.0 (15/20)	63.6 (14/22)	.26	68.2 (15/22)	85.0 (17/20)	.32	.20
Physical Examination	Baseline			Posttreatment			
PFM strength: Brinks' score (range, 3-12)	5.9 (1.1) (n = 28)	5.9 (1.3) (n = 25)	.42	5.5 (1.5) (n = 28)	5.6 (1.3) (n = 23)	.43	.17
Anal strength: DRESS score (range, 1-12)	5.2 (1.2) (n = 27)	5.1 (1.7) (n = 23)	.58	5.2 (1.6) (n = 26)	5.3 (1.2) (n = 21)	.38	.63
Timed Up and Go, s	12.1 (3.2) (n = 25)	12.1 (4.0) (n = 25)	.52	14.5 (8.8) (n = 27)	16.1 (11.6) (n = 24)	.71	.06

Abbreviations: DRESS, Digital Rectal Examination Scoring System; ICIQ, International Consultation on Incontinence Modular Questionnaire; OAB, overactive bladder; PFM, pelvic floor muscle; UI, urinary incontinence; UUI, urgency UI.

¹Data included in table from women who completed the study.

²P value for within-group change.

³P value for between-group change.

⁴Improvement and satisfaction with treatment only applies to treatment response at 6 and 12 weeks. Data are given as percentage (number/total).

arm (2.6 ± 2.1 vs 3.7 ± 2.6 ; $P = .05$). Serum 25(OH)D levels were higher in the vitamin D arm compared to the placebo arm (21.2 vs 18.2 ng/mL; $P = .05$) at baseline, with increases only seen in the vitamin D arm at 6 and 12 weeks ($P < .001$, Supplemental Figure 2). Adherence to therapy was approximately 97.7% across all arms (96.2% for vitamin D compared to 99.3% for placebo; $P = .75$).

When evaluating the overall percentage change in UUI episodes (Figure 1 and Supplemental Table 2), we found larger reductions for UUI episodes in the vitamin D arm compared to the placebo arm for the women completing the study and the intention-to-treat analysis. In further exploratory analysis among high-risk subgroups (Figure 1), black women ($n = 33$) had greater reductions in UUI episodes with vitamin D compared to placebo. In obese women ($n = 32$), reduction in UUI episodes did not differ by arm.

Seven-day bladder diary (Table 2) data were used to calculate within- and between-arm 12-week changes in daytime frequency, nocturia episodes, daytime urgency, and nighttime urgency. Women in both arms experienced improvements in daytime urgency, but without between-arm differences. We did not find significant differences between arms in daytime voiding frequency or nocturia episodes. However, women in the placebo arm had improvement in nighttime urgency scores.

We found no between-arm differences for the 12-week change in UI and OAB severity questionnaires, nor were there differences in perceived improvement of satisfaction with treatment (Table 2). We also found no between-arm differences in changes in pelvic floor muscle strength, anal sphincter muscle strength, or Timed Up and Go testing.

With regard to adverse events (Supplemental Table 3), one hospitalization occurred for women on vitamin D who had palpitations. Two participants in the vitamin D arm experienced transient asymptomatic hypercalcemia at 6 weeks ($P = .04$ between groups) that resolved at 12 weeks ($P = .68$) after holding vitamin D₃. Gastrointestinal symptoms were higher among women taking vitamin D compared to placebo.

DISCUSSION

We designed and conducted a pilot clinical trial to address the impact of optimal vitamin D levels for improving UUI. Although some groups advocate vitamin D levels of 30 ng/mL or greater, the Institute of Medicine defines vitamin D repletion as a level of 20 ng/mL or less.²² Among postmenopausal women with vitamin D insufficiency and UUI, high-dose cholecalciferol had a smaller than predicted effect compared to placebo, which had a larger, unanticipated effect on UUI episodes after 12 weeks. Our pilot study results provide data to support future studies with adequate power for determining the effects of vitamin D for improving UUI with maintained serum 25(OH)D levels at 30 ng/mL or greater, especially among black women who may have higher risk for vitamin D insufficiency and UUI.

Even if vitamin D alone does not improve UUI in a larger clinical trial, repleting women with vitamin D insufficiency may help improve outcomes related to other UUI treatments. Increasing evidence in humans and rats has shown that vitamin D may be involved in the regulation of

detrusor muscle contraction.^{2,23} Using vitamin D or vitamin D analogues may decrease detrusor overactivity when used with other antimuscarinic agents, or other behavioral interventions, especially in women who have vitamin D deficiency.

Recent data also suggest a need to identify women at higher risk of vitamin D insufficiency, such as black women and obese women. OAB symptoms and UUI disproportionately occur in black women,²⁴ and vitamin D deficiency is common as well (pigmentation reduces vitamin D production).²⁵ To our knowledge, no large studies of vitamin D and bladder symptoms have focused on black women. Additionally, obesity lowers bioavailability of vitamin D,²⁵ and obesity is a risk factor for OAB and UUI; yet, no studies have examined how vitamin D supplements may reduce bladder symptoms in obese women. Our results suggest that black women may have larger reductions in UUI episodes with vitamin D supplementation compared to placebo. However, obese women did not have similar responses to vitamin D supplementation.

Our trial has strengths and limitations. We recruited a high percentage of treatment-naïve women (62%) and African American women with UUI (71%). Attrition was low (10%), adherence to study medication was excellent, and the dosing regimen was effective in raising serum 25(OH)D. The 25(OH)D levels were measured by a laboratory that maintains high-quality standards and is VitDQAP approved.¹¹ Finally, we adjusted cholecalciferol doses to maintain 25(OH)D levels greater than 30 ng/mL in the high-dose arm, with sham adjustments in other arms to maintain blinding. Limitations include that individuals participated for only 12 weeks; perhaps longer exposure to high-dose cholecalciferol would yield greater effects on improving UUI episodes. Self-monitoring using the bladder diary could have had some impact to reduce UUI in both groups by increasing attention to urgency episodes. Last, we were not able to recruit the sample size needed for sufficient power to detect differences between the groups for this pilot study. Based on the effect size in this pilot study, a total of 548 women with UUI and low 25(OH)D would provide sufficient power to detect differences in a larger study.

Twelve weeks of high-dose cholecalciferol given to postmenopausal women with 25(OH)D levels less than 30 ng/mL had a lower than expected effect size on UUI without clinically meaningful beneficial effects on other bladder symptoms, pelvic floor muscle function, or functional status. In an exploratory subgroup analysis, black women with UUI and low vitamin D did have at least a 40% improvement in UUI with high-dose cholecalciferol. Further investigation of vitamin D₃ alone or in combination with other treatments for UUI may be warranted.

ACKNOWLEDGMENTS

The authors would like to thank all study participants and study staff involved. Laurie Slay provided research coordination and data oversight for this study.

Financial Disclosure: This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (1R21DK096201) and grants from the National Center for Advancing Translational Sciences of the

National Institutes of Health (NIH) under awards UL1TR002378 and UL1TR001417. Additional funding was provided from the NIH Office on Research in Women's Health.

Conflicts of Interest: H.E.R.: UpToDate, Renovia. All other authors have no conflicts to declare.

Author Contributions: A.D.M.: Study concept and design, data analysis and interpretation, manuscript preparation.

T.M.B.: Study concept and design, data analysis and interpretation, manuscript preparation.

V.T.: Study concept and design, data analysis and interpretation, manuscript preparation.

C.V.: Study concept, data analysis and interpretation, manuscript preparation.

H.E.R.: Study concept and design, data analysis and interpretation, manuscript preparation.

K.L.B.: Study concept and design, data analysis and interpretation, manuscript preparation.

P.S.G.: Study concept and design, data analysis and interpretation, manuscript preparation.

Sponsor's Role: The National Institutes of Health had no role in the collection, analysis, and interpretation of the data or the manuscript preparation, review, or approval. The contents of this article do not represent the views of the US Department of Veterans Affairs or the US Government.

REFERENCES

- Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. *Histochem J*. 2001;33:19-24.
- Crescioli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands. *J Clin Endocrinol Metab*. 2005;90:962-972.
- Badalian SS, Rosenbaum PF. Vitamin D and pelvic floor disorders in women: results from the National Health and Nutrition Examination Survey. *Obstet Gynecol*. 2010;115:795-803.
- Lee HS, Lee JH. Vitamin D and urinary incontinence among Korean women: a propensity score-matched analysis from the 2008-2009 Korean National Health and Nutrition Examination Survey. *J Korean Med Sci*. 2017;32:661-665.
- Dallosso HM, McGrother CW, Matthews RJ, Donaldson MM, Leicestershire MRC Incontinence Study Group. Nutrient composition of the diet and the development of overactive bladder: a longitudinal study in women. *NeurourolUrodyn*. 2004;23:204-210.
- Parker-Autry C, Houston DK, Rushing J, et al. Characterizing the functional decline of older women with incident urinary incontinence. *Obstet Gynecol*. 2017;130:1025-1032.
- Vaughan CP, Tangpricha V, Motahar-Ford N, et al. Vitamin D and incident urinary incontinence in older adults. *Eur J Clin Nutr*. 2016;70(9):987-989.
- Oberg J, Verelst M, Jorde R, Cashman K, Grimnes G. High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women. *J Steroid Biochem Mol Biol*. 2017;173:28-32.
- Digesu GA, Verdi E, Cardozo L, Olivieri L, Khullar V, Colli E. Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity. *Urology*. 2012;80:48-54.
- Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. *J Am Geriatr Soc*. 2003; 51:1451-1454.
- Bedner M, Lippa KA, Tai SS. An assessment of 25-hydroxyvitamin D measurements in comparability studies conducted by the vitamin D metabolites quality assurance program. *Clin Chim Acta*. 2013;426:6-11.
- Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. *J Clin Epidemiol*. 2005;58: 595-602.
- Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. *Obstet Gynecol*. 1988;71:812-817.
- Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. *J Urol*. 2005;174:604-607.
- Abrams P, Avery K, Gardener N, Donovan J. The International Consultation on Incontinence Modular Questionnaire: www.icicq.net. *J Urol*. 2006;175:1063-1066.
- Sirls LT, Tennstedt S, Brubaker L, et al. The minimum important difference for the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form in women with stress urinary incontinence. *NeurourolUrodyn*. 2015;34:183-187.
- Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). *Qual Life Res*. 2005;14:849-855.
- Burgio KL, Goode PS, Richter HE, Locher JL, Roth DL. Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings. *NeurourolUrodyn*. 2006;25:411-417.
- FitzGerald MP, Burgio KL, Borello-France DF, et al. Pelvic-floor strength in women with incontinence as assessed by the brink scale. *Phys Ther*. 2007; 87:1316-1324.
- Orkin BA, Sinykin SB, Lloyd PC. The Digital Rectal Examination Scoring System (DRESS). *Dis Colon Rectum*. 2010;53:1656-1660.
- Viccaro LJ, Perera S, Studenski SA. Is timed up and go better than gait speed in predicting health, function, and falls in older adults? *J Am Geriatr Soc*. 2011;59:887-892.
- Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab*. 2011;96: 53-58.
- Wrobel A, Rechberger T. The influence of maxacalcitol, vitamin D3 analog, on detrusor overactivity in conscious rats. *Urology*. 2016;93:224. e7-e15.
- Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. *NeurourolUrodyn*. 2013;32:230-237.
- Heaney RP, Armas LA. Quantifying the vitamin D economy. *Nutr Rev*. 2015;73:51-67.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article.

Supplemental Figure 1: CONSORT diagram and study flow.

Supplemental Figure 2: Serum vitamin 25-hydroxyvitamin D (25[OH]D) levels by allocation group over time.

Supplemental Table 1: Vitamin D and Urgency UI Pilot Study Inclusion and Exclusion Criteria

Supplemental Table 2: Percentage Change in Total UII Episodes Overall and Among Women in High-Risk Subgroups

Supplemental Table 3: Adverse Events by Treatment Arm